Pricing Log in Create free account

BridgeBio Pharma, Inc. (BBIO) vs Halozyme Therapeutics, Inc. (HALO)

BridgeBio Pharma, Inc. and Halozyme Therapeutics, Inc. are both Biotechnology companies. BridgeBio Pharma, Inc. and Halozyme Therapeutics, Inc. are of similar size ($13.8B and $13.1B). BridgeBio Pharma, Inc. has negative trailing earnings, so its P/E is not meaningful; Halozyme Therapeutics, Inc. trades at 34.6×. BridgeBio Pharma, Inc. grew revenue faster over the last twelve months: 202.4% against 41.2%. Halozyme Therapeutics, Inc. has the higher net margin (24.9% vs −97.0%) and the higher return on invested capital (18.1% vs 0.00%). Across the 18 metrics below, Halozyme Therapeutics, Inc. leads on 13 and BridgeBio Pharma, Inc. on 5.

Valuation

Metric BBIO HALO Biotechnology median
P/E n/m 34.61 8.50
P/S 18.23 8.59 9.71
P/B n/m 99.54 2.13
Price to free cash flow n/m 17.72 20.82
EV/EBITDA n/m 22.53 0.64
EV/Sales 19.93 9.74 9.21
Earnings yield (5.38%) 2.89% (33.15%)
Free cash flow yield (3.41%) 5.64% (25.50%)

Profitability

Metric BBIO HALO Biotechnology median
Gross margin 94.44% 82.42% 65.16%
Operating margin (69.81%) 35.90% 0.00%
Net margin (97.03%) 24.86% 0.00%
Free cash flow margin (61.06%) 48.46% 0.00%
Return on equity 32.31% 173.67% (56.36%)
Return on assets (60.23%) 17.86% (48.04%)
Return on invested capital 0.00% 18.13% 0.00%

Growth

Metric BBIO HALO Biotechnology median
Revenue growth (TTM) 202.39% 41.15% 6.02%
EPS growth (last fiscal year) (31.25%) (25.36%) 30.26%
Revenue growth, 5-year CAGR 127.44% 39.16% 9.41%
Net income growth, 5-year CAGR 0.00% 19.68% 0.00%

Health

Metric BBIO HALO Biotechnology median
Debt to equity (0.77) 14.95 0.00
Current ratio 1.23 2.71 4.72
Net debt to EBITDA (2.47) 3.56 0.96

Dividend

Metric BBIO HALO Biotechnology median
Dividend yield — — 0.09%
Payout ratio — — —

Size

Metric BBIO HALO Biotechnology median
Market cap 13.12b 13.79b 135.18m

Compare with another peer

Any metric, up to five companies and an Excel export Powerpack